Limitations of Current Treatments for Chronic Active Lesions
Chronic active lesions are increasingly recognised as a key driver of long-term disability in MS, yet most clinical trials lack the tools to measure them precisely. We offer pharmaceutical and biotech companies a validated, automated solution for quantifying chronic lesion tissue expansion as a trial endpoint.
Our LEAP pipeline has been applied in commercial analyses evaluating the effect of natalizumab, fingolimod, ocrelizumab, and cladribine on smouldering inflammation across multi-site Australian cohorts, and in independent trial analyses for Merck and REKOVER. We have also published the sample size requirements for CLTE-based trial endpoints, providing a direct basis for trial planning and power calculations.
What we can provide:
- Retrospective CLTE analysis on existing trial MRI datasets
- Prospective integration of LEAP into trial design and endpoint selection
- Sample size and power calculations for CLTE-based endpoints
- Multi-site data harmonisation and quality control
If you are interested in applying CLTE analysis to your programme, contact us.
We designed COMPASS-MS, a pioneering international study comparing the effectiveness of different disease-modifying therapies on smouldering inflammation. Using our LEAP methodology across multiple international centers, this multi-center investigation analyzes existing patient data to establish the first comprehensive comparison of current treatments.
We developed a novel approach to clinical trials focusing on smouldering inflammation, showing how chronic lesion expansion can serve as a powerful and efficient endpoint. Our research demonstrates that meaningful treatment effects can be detected with smaller patient groups, creating new opportunities for evaluating targeted therapies while maintaining robust scientific standards.
MS Lesion Analytics 